ClinicalTrialsFinder
RecruitingPhase 3NCT06658353

Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Single-arm, Open, Multi-center Phase III Clinical Study to Assess the Safety and Effectiveness of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Enrollment

54 participants

Start Date

Mar 17, 2025

Study Type

INTERVENTIONAL

Conditions

Locally Advanced Solid Tumor

Summary

This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VC004 Capsules for people with locally advanced solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVC004 Capsules

VC004 Capsules BID

Locations(1)

Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06658353

Related Trials

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

NCT0573283126 locations

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

NCT0721381712 locations

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT0591926433 locations

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

NCT069754104 locations

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT0538462674 locations